Literature DB >> 21247634

Treating myelodysplastic syndrome improves an accompanying autoimmune disease along with a reduction in regulatory T-cells.

Omar Al Ustwani, Jawad Francis, Paul K Wallace, Julian Ambrus, Meir Wetzler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21247634      PMCID： PMC3079022          DOI： 10.1016/j.leukres.2010.12.015

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  10 in total

1.  CD4 CD25high regulatory T cells are not impaired in patients with primary Sjögren's syndrome.

Authors:  Jacques-Eric Gottenberg; Frédéric Lavie; Karim Abbed; Jacques Gasnault; Emilie Le Nevot; Jean-François Delfraissy; Yassine Taoufik; Xavier Mariette
Journal:  J Autoimmun       Date:  2005-05       Impact factor: 7.094

2.  Effect of steroids on the frequency of regulatory T cells and expression of FOXP3 in a patient with systemic lupus erythematosus: a two-year follow-up.

Authors:  Al-M Cepika; I Marinic; J Morovic-Vergles; D Soldo-Juresa; A Gagro
Journal:  Lupus       Date:  2007       Impact factor: 2.911

3.  Quantification of regulatory T cells in peripheral blood of patients with systemic lupus erythematosus.

Authors:  Mojtaba Habibagahi; Zahra Habibagahi; Mansooreh Jaberipour; Amir Aghdashi
Journal:  Rheumatol Int       Date:  2010-04-02       Impact factor: 2.631

4.  Isolation and functional characterization of regulatory CD25brightCD4+ T cells from the target organ of patients with rheumatoid arthritis.

Authors:  Duojia Cao; Vivianne Malmström; Clare Baecher-Allan; David Hafler; Lars Klareskog; Christina Trollmo
Journal:  Eur J Immunol       Date:  2003-01       Impact factor: 5.532

5.  CD4+CD25+ regulatory T cells (TREG) in systemic lupus erythematosus (SLE) patients: the possible influence of treatment with corticosteroids.

Authors:  N A Azab; I H Bassyouni; Y Emad; G A Abd El-Wahab; G Hamdy; M A Mashahit
Journal:  Clin Immunol       Date:  2008-03-04       Impact factor: 3.969

6.  Validated protocol for FoxP3 reveals increased expression in type 1 diabetes patients.

Authors:  Jean Grant; Katarzyna Bourcier; Stephen Wallace; Dalin Pan; Alexis Conway; Vicki Seyfert-Margolis; Paul K Wallace
Journal:  Cytometry B Clin Cytom       Date:  2009-03       Impact factor: 3.058

Review 7.  Myelodysplasia-associated autoimmunity: clinical and pathophysiologic concepts.

Authors:  M Voulgarelis; S Giannouli; K Ritis; A G Tzioufas
Journal:  Eur J Clin Invest       Date:  2004-10       Impact factor: 4.686

8.  Activation of cytotoxic T-cell receptor gammadelta T lymphocytes in response to specific stimulation in myelodysplastic syndromes.

Authors:  Jean-Jacques Kiladjian; Géraldine Visentin; Emilie Viey; Sylvie Chevret; Virginie Eclache; Jerome Stirnemann; Jean Henri Bourhis; Salem Chouaib; Pierre Fenaux; Anne Caignard
Journal:  Haematologica       Date:  2008-02-11       Impact factor: 9.941

9.  CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS).

Authors:  Shahram Y Kordasti; Wendy Ingram; Janet Hayden; David Darling; Linda Barber; Behdad Afzali; Giovanna Lombardi; Marcin W Wlodarski; Jaroslaw P Maciejewski; Farzin Farzaneh; Ghulam J Mufti
Journal:  Blood       Date:  2007-04-05       Impact factor: 22.113

10.  Low frequency of CD4+CD25+ Treg in SLE patients: a heritable trait associated with CTLA4 and TGFbeta gene variants.

Authors:  Marta Barreto; Ricardo C Ferreira; Lara Lourenço; Maria F Moraes-Fontes; Eugénia Santos; Miguel Alves; Cláudia Carvalho; Berta Martins; Rita Andreia; João F Viana; Carlos Vasconcelos; Luísa Mota-Vieira; Carlos Ferreira; Jocelyne Demengeot; Astrid M Vicente
Journal:  BMC Immunol       Date:  2009-01-27       Impact factor: 3.615
  10 in total
  5 in total

1.  Impact of azacitidine on red blood cell alloimmunisation in myelodysplastic syndrome.

Authors:  Sebastián Ortiz; Maria T Orero; Karla Javier; Carolina Villegas; Irene Luna; Pedro Pérez; Mónica Roig; María López; Sofía Costa; Félix Carbonell; Rosa Collado; David Ivars; Mariano Linares
Journal:  Blood Transfus       Date:  2016-06-24       Impact factor: 3.443

Review 2.  Myelodysplastic syndromes and autoimmune diseases--case series and review of literature.

Authors:  Omar Al Ustwani; Laurie A Ford; Sheila J N Sait; Anne Marie W Block; Maurice Barcos; Carlos E Vigil; Elizabeth A Griffiths; James E Thompson; Eunice S Wang; Julian Ambrus; Meir Wetzler
Journal:  Leuk Res       Date:  2013-05-18       Impact factor: 3.156

3.  5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies.

Authors:  A O Gang; T M Frøsig; M K Brimnes; R Lyngaa; M B Treppendahl; K Grønbæk; I H Dufva; P Thor Straten; S R Hadrup
Journal:  Blood Cancer J       Date:  2014-03-28       Impact factor: 11.037

4.  Pseudogout: An Autoimmune Paraneoplastic Manifestation of Myelodysplastic Syndrome.

Authors:  Shumaila M Iqbal; Hafiz M Aslam; Faizan Faizee; Sana Qadir; Saadia Waheed
Journal:  Cureus       Date:  2018-09-27

Review 5.  Inflammatory arthritis in patients with myelodysplastic syndromes: a multicenter retrospective study and literature review of 68 cases.

Authors:  Arsène Mekinian; Thorsten Braun; Olivier Decaux; Géraldine Falgarone; Eric Toussirot; Loic Raffray; Mohamed Omouri; Bruno Gombert; Benoit De Wazieres; Anne-Laure Buchdaul; Jean-Marc Ziza; David Launay; Guillaume Denis; Serge Madaule; Christian Rose; Eric Grignano; Pierre Fenaux; Olivier Fain
Journal:  Medicine (Baltimore)       Date:  2014-01       Impact factor: 1.889
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.